Age-related heterogeneity in immune responses to SARS-CoV-2 vaccine BNT162b2

Dami A. Collier,Isabella A.T.M. Ferreira,Prasanti Kotagiri,Rawlings Datir,Eleanor Lim,Emma Touzier,Bo Meng,Adam Abdullahi,Anne Elmer,Nathalie Kingston,Barbara Graves,Emma Le Gresley,Daniela Caputo,Kenneth GC Smith,John R. Bradley,Lourdes Ceron-Gutierrez,Paulina Cortes-Acevedo,Gabriela Barcenas-Morales,Michelle Linterman,Laura McCoy,Chris Davis,Emma Thomson,Paul A. Lyons,Eoin McKinney,Rainer Doffinger,Mark Wills,Ravindra K. Gupta,

DOI: https://doi.org/10.1101/2021.02.03.21251054

2021-02-05

Abstract:Abstract Two dose mRNA vaccination provides excellent protection against SARS-CoV-2. However, there are few data on vaccine efficacy in elderly individuals above the age of 80 1 . Additionally, new variants of concern (VOC) with reduced sensitivity to neutralising antibodies have raised fears for vulnerable groups. Here we assessed humoral and cellular immune responses following vaccination with mRNA vaccine BNT162b2 2 in elderly participants prospectively recruited from the community and younger health care workers. Median age was 72 years and 51% were females amongst 140 participants. Neutralising antibody responses after the first vaccine dose diminished with increasing age, with a marked drop in participants over 80 years old. Sera from participants below and above 80 showed significantly lower neutralisation potency against B.1.1.7, B.1.351 and P.1. variants of concern as compared to wild type. Those over 80 were more likely to lack any neutralisation against VOC compared to younger participants following first dose. The adjusted odds ratio for inadequate neutralisation activity against the B.1.1.7, P.1 and B.1.351 variant in the older versus younger age group was 4.3 (95% CI 2.0-9.3, p<0.001), 6.7 (95% CI 1.7-26.3, p=0.008) and 1.7 (95% CI 0.5-5.7, p=0.41). Binding IgG and IgA antibodies were lower in the elderly, as was the frequency of SARS-CoV-2 Spike specific B-memory cells. We observed a trend towards lower somatic hypermutation in participants with suboptimal neutralisation, and elderly participants demonstrated clear reduction in class switched somatic hypermutation, driven by the IgA1/2 isotype. SARS-CoV-2 Spike specific T-cell IFNγ and IL-2 responses fell with increasing age, and both cytokines were secreted primarily by CD4 T cells. We conclude that the elderly are a high risk population that warrant specific measures in order to mitigate against vaccine failure, particularly where variants of concern are circulating.